2025-08-07: DEUSG Virtual

Opening

5 min

Shane Byrnes 

Alejandro Lopez Osornio

Welcome & Notification of Recording

Unit of Measure - rationalisation of concepts

15 min

Emma Melhuish (Unlicensed) 

Overview of proposal from UK, and group discussion/feedback.

Link to discussion & proposal paper: Unit of Measure - rationalisation of concepts

Additional Attributes

15 min

Yongsheng Gao 

Slides attached at end of this meeting page.

1. Yong has added a comment to the discussion board:
https://snomed.atlassian.net/wiki/display/USRG/Additional+Attributes+for+National+Drug+Extensions
This includes a proposed new MRCM for 30465011000036106 |Has container type (attribute)|. Yong has raised questions regarding the domain, range (especially with respect to specific physical object values), and cardinality (also consider multi-container products, subpacks, and the implications for classification).

2. The attributes list from Canada is also available on the discussion board. Additional relevant content can be found on this page:
https://snomed.atlassian.net/wiki/display/USRG/Medication+MRCM+Extensions

What are members requirements in the area of additional attributes?

Substances Co-Ordination Update

5 min

Alejandro Lopez Osornio 

 Update:

• Substances in multiple countries - target for release for October 1st.

• Substances in single country - c. 30 concepts promoted and c. 150 concepts underway. Work will continue across 2025 and into 2026.

• Collaborations team linking in with organisations (e.g. EMA, FDA) to look at options for maintaining substance aligned longer term. 

Strength Representation in Vaginal Ring

5 min

Nicola Ingram 

Request for feedback on Patches strength representation

Group feedback on applying ongoing patch strength changes to Vaginal Rings

Streamlining of Editorial Policy

5 min

Alejandro Lopez Osornio

Consolidation of Medicinal Product Model Document into the Editorial Guide.

AOB

5 min

Topic Back log

• Less Granular Clinical Drug

• Elemental Substances (Matt, AUS)

• Substances Co-ordination (MF/2025 Priority topic)

  • Step 1: Substances in multiple extensions Batch promotions complete, SI review and authoring underway

  • Step 2: Substances in one extension

  • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)

• Medication Stopped v Medication Discontinued (Karen, SI)

• Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)

• Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 

• Increase range of has active ingredient to include microorganisms and natural products (Guillermo)

• Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-68

• Units of Measure - proposal for rationalisation of concepts (Emma, UK)

• Rounding rules - update on where SI is at with current guidance (Linda, CA)

Done or in progress:

• Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG

• Group Input on Patch Strength Representation Briefing note now being implemented

• Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site

• Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue

• Value range of a |Has container type| attribute (Linda, CA)

• Routes of Administration - Implementation Considerations (Mia, NZ)